Skip to product information
1 of 1

CEBPD Recombinant Rabbit mAb (S-1932-47)

CEBPD Recombinant Rabbit mAb (S-1932-47)

Catalog Number: S0B1348 Application: WB Reactivity: Human Conjugation: Unconjugated Brand: Starter
Price:
Regular price $130.00 SGD
Regular price Sale price $130.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rabbit
Antigen CEBPD
Synonyms CCAAT/enhancer-binding protein delta; C/EBP delta; Nuclear factor NF-IL6-beta (NF-IL6-beta)
Immunogen Synthetic Peptide
Location Nucleus
Accession P49716
Clone Number S-1932-47
Antibody Type Recombinant mAb
Isotype IgG
Application WB
Reactivity Hu
Positive Sample LoVo, Caco-2, HaCaT, MDA-MB-231
Predicted Reactivity Bv, Sh
Purification Protein A
Concentration 0.5 mg/ml
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, -20 °C as supplied

Dilution


application dilution species
WB 1:1000 Hu

Background

CEBPD (CCAAT/enhancer-binding protein delta) is a bZIP (basic leucine zipper) transcription factor that plays a crucial role in regulating cellular processes such as inflammation, cell growth, and apoptosis. It is induced by Toll-like receptor 4 (TLR4) signaling and is essential for the expression of many lipopolysaccharide (LPS)-induced genes, contributing to the clearance of bacterial infections. CEBPD functions as a tumor suppressor by inducing growth arrest and apoptosis in cancer cells, and its expression is often reduced in various cancers due to site-specific methylation. In glioblastoma, CEBPD acts as a master transcription factor controlling hypoxia-regulated genes and promotes tumor invasion through the ECM-integrin-mediated EGFR/PI3K pathway. Specifically, it activates the EGFR/PI3K/AKT pathway by directly binding to and regulating the expression of key ECM proteins such as fibronectin (FN1), which enhances the invasive capacity of cancer cells under hypoxic conditions. This highlights CEBPD as a potential therapeutic target in cancers with hypoxic microenvironments.

Picture

Western Blot

WB result of CEBPD Recombinant Rabbit mAb
Primary antibody: CEBPD Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: LoVo whole cell lysate 20 µg
Lane 2: Caco-2 whole cell lysate 20 µg
Lane 3: HaCaT whole cell lysate 20 µg
Lane 4: MDA-MB-231 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 28 kDa
Observed MW: 32 kDa
This blot was developed with high sensitivity substrate

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)